Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.60 |
| ▸ | PIK3R2 | O00459 | 5/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21174714 | 0.92 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL21174690 | 0.89 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL16583340 | 0.88 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3R1PIK3R2 | |
| SCHEMBL16583272 | 0.85 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL21174761 | 0.84 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL16583241 | 0.84 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL21174765 | 0.84 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL21174720 | 0.83 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL21174812 | 0.81 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA | |
| SCHEMBL21174810 | 0.81 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R1PIK3R2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751339-B2 | Substituted aminopyrimidine compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| US-20190224197-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224197-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3R1, PIK3R3 | PIK3CD 4/4885PIK3CG 8/4885PIK3R1 2/4885 |
| US-10751339-B2 | Substituted aminopyrimidine compounds and methods of use | PIK3CA, PIK3CD, MYD88 | PIK3CD 2/4885PIK3CG 6/4885PIK3R1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.